Stereotactic Radiation Improves Quality of Life for Patients With Multiple Brain Metastases

Randomized trial shows stereotactic radiation outperforms whole-brain radiation on key patient-reported outcomes.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

A randomized trial found that stereotactic radiation therapy improved symptom severity and interference with daily functioning compared to hippocampal-avoidance whole-brain radiation therapy (HA-WBRT) in patients with 5 to 20 brain metastases. While there were no significant differences in neurocognitive screening or self-reported cognitive symptoms, the stereotactic radiation group showed better performance on several specific neurocognitive tests.

Why it matters

This study provides important evidence that stereotactic radiation should be considered the standard of care for patients with multiple brain metastases, as it offers meaningful quality-of-life benefits without compromising survival compared to the previous standard of HA-WBRT.

The details

The randomized trial included 196 patients with 5 to 20 brain metastases who were treated at four U.S. centers between 2017 and 2024. Patients received either stereotactic radiation or HA-WBRT. The primary endpoint was the change in the weighted composite MD Anderson Symptom Inventory-Brain Tumor score, which measures symptom severity and interference with daily functioning. At 6 months, the stereotactic radiation group showed a decrease in this score from 2.69 to 2.37, while the HA-WBRT group increased from 2.29 to 3.03, a statistically significant difference.

  • The trial enrolled patients from April 2017 to May 2024.
  • The primary endpoint was measured at 6 months.

The players

Ayal A. Aizer, MD, MHS

Researcher at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, and lead author of the study.

Michael Chan, MD

Researcher at the Wake Forest School of Medicine in Winston-Salem, North Carolina, and author of an accompanying editorial.

Got photos? Submit your photos here. ›

What they’re saying

“The results underscore a paradigm shift toward precision techniques that prioritize patient well-being.”

— Ayal A. Aizer, MD, MHS, Researcher (JAMA)

“Given the rigorous study design and the clinically meaningful benefits seen, it is reasonable for its results to influence clinical practice. However, a universal shift in the standard of care may be premature and pending the results of the confirmatory study.”

— Michael Chan, MD, Researcher (JAMA)

What’s next

The Canadian Cancer Trials Group CE.7 trial, a phase III study comparing stereotactic radiation to HA-WBRT for patients with five to 15 brain metastases, could provide additional confirmation of these findings.

The takeaway

This study suggests stereotactic radiation should be considered the new standard of care for patients with multiple brain metastases, as it offers significant quality-of-life benefits over the previous standard of whole-brain radiation while maintaining similar survival outcomes.